Related changes

Jump to: navigation, search

Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.

Recent changes options
Legend:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes
Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide registered users | Hide anonymous users | Hide my edits | Show bots | Hide minor edits
Show new changes starting from 22:55, 19 October 2020
   
Page name:

15 October 2020

     12:39  Pembrolizumab (Keytruda)‎ (diff | hist) . . (+465). . PeterYang (talk | contribs) (Classical Hodgkin lymphoma (cHL): FDA approval) (Tag: Visual edit)

13 October 2020

 m   20:47  Melanoma - null regimens‎ (diff | hist) . . (+633). . Jwarner (talk | contribs) (Placebo)
 m   20:47  Melanoma‎‎ (2 changes | history) . . (+633). . [Jwarner‎ (2×)]
 m    20:47 (cur | prev) . . (0). . Jwarner (talk | contribs) (Regimen variant #3, 3 years {{#subobject:a17a88|Variant=1}})
 m    20:46 (cur | prev) . . (+633). . Jwarner (talk | contribs) (Ipilimumab monotherapy {{#subobject:89bbc6|Regimen=1}})
 m   15:36  Melanoma, BRAF-mutated‎ (diff | hist) . . (+6). . Jwarner (talk | contribs) (Regimen {{#subobject:abc29f|Variant=1}})